ICRT14

ICRT14 is a small molecule inhibitor belonging to the thiazolidinedione class that specifically inhibits β-catenin responsive transcription by blocking the interaction between β-catenin and TCF4 without affecting other β-catenin interactions[1][3][4]. It potently suppresses the canonical Wnt/β-catenin signaling pathway, a pathway implicated in a variety of cancers and other proliferative diseases. ICRT14 inhibits the proliferation of colorectal and cervical cancer cells by disrupting transcriptional activity of β-catenin/TCF, induces cell cycle arrest, and reduces tumor growth in vivo[1][3][4]. Its downstream targeting of β-catenin/TCF makes it effective even against cancers with β-catenin mutations. ICRT14 is a research compound and is not approved for clinical use.

Brand names

ICRT14ICRT-14ICRT 14

Other names

ICRT14ICRT-14ICRT 14